Nephros (NEPH) PEG Ratio: History & Chart

Nephros, Inc.(NEPH)

Medical - Instruments & Supplies · South Orange, NJ

$3.68+0.13 (+3.69%)

Delayed quote: Oct 6, 2026, 12:25 PM EDT

About Nephros, Inc.

Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.

South Orange, NJ

36 employees

www.nephros.com

Healthcare / Medical - Instruments & Supplies

Sector: Healthcare
Industry: Medical - Instruments & Supplies
CEO: Robert Banks

View full financials

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Nephros, Inc. (NEPH)	$39.96M	N/A	N/A	N/A	N/A
Metagenomi, Inc. Common Stock (MGX)vs ›	$40.28M	N/A	N/A	N/A	N/A
Filana Therapeutics, Inc. (FLNA)vs ›	$40.36M	N/A	N/A	N/A	N/A
Harvard Bioscience, Inc. (HBIO)vs ›	$39.08M	N/A	0.32	0.32	0.32
Incannex Healthcare Limited (IXHL)vs ›	$38.05M	N/A	N/A	N/A	N/A
BioStem Technologies, Inc. (BSEM)vs ›	$42.29M	N/A	N/A	N/A	N/A
Edesa Biotech, Inc. (EDSA)vs ›	$37.33M	N/A	N/A	N/A	N/A
Precipio, Inc. (PRPO)vs ›	$42.63M	N/A	N/A	N/A	N/A
QT Imaging Holdings, Inc. (QTI)vs ›	$36.76M	N/A	N/A	N/A	N/A
Elicio Therapeutics, Inc. (ELTX)vs ›	$36.42M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PEG RATIO

TTM

Nephros, Inc. (NEPH)

$39.96M

N/A

Metagenomi, Inc. Common Stock (MGX)vs ›

$40.28M

N/A

Filana Therapeutics, Inc. (FLNA)vs ›

$40.36M

N/A

Harvard Bioscience, Inc. (HBIO)vs ›

$39.08M

N/A

0.32

Incannex Healthcare Limited (IXHL)vs ›

$38.05M

N/A

BioStem Technologies, Inc. (BSEM)vs ›

$42.29M

N/A

Edesa Biotech, Inc. (EDSA)vs ›

$37.33M

N/A

Precipio, Inc. (PRPO)vs ›

$42.63M

N/A

QT Imaging Holdings, Inc. (QTI)vs ›

$36.76M

N/A

Elicio Therapeutics, Inc. (ELTX)vs ›

$36.42M

N/A

PEG Ratio Formula & Definition

PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)

The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.

PEG Ratio: N/A

NEPH PEG Ratio Metrics

NEPH Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

Related Metrics